1. Home
  2. EQS vs MRKR Comparison

EQS vs MRKR Comparison

Compare EQS & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equus Total Return Inc.

EQS

Equus Total Return Inc.

HOLD

Current Price

$1.31

Market Cap

18.9M

Sector

Finance

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$2.06

Market Cap

16.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQS
MRKR
Founded
1991
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
16.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EQS
MRKR
Price
$1.31
$2.06
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$10.17
AVG Volume (30 Days)
24.9K
359.0K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,377,000.00
$4,694,988.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.11
N/A
52 Week Low
$0.74
$0.81
52 Week High
$2.49
$4.07

Technical Indicators

Market Signals
Indicator
EQS
MRKR
Relative Strength Index (RSI) 25.99 73.26
Support Level $1.27 $1.45
Resistance Level $1.44 $1.55
Average True Range (ATR) 0.13 0.16
MACD -0.03 0.07
Stochastic Oscillator 9.32 66.94

Price Performance

Historical Comparison
EQS
MRKR

About EQS Equus Total Return Inc.

Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Share on Social Networks: